卵巢癌化疗的实际考虑因素。
Practical considerations in ovarian cancer chemotherapy.
机构信息
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd, Duarte, CA 91010, USA.
出版信息
Ther Adv Med Oncol. 2010 May;2(3):175-87. doi: 10.1177/1758834010361333.
Abstract
Epithelial ovarian cancer remains the most lethal gynecologic malignancy despite advances in treatment. The standard management generally involves a combination of surgical tumor debulking and chemotherapy. Over the decades, chemotherapy for ovarian cancer has evolved and currently involves a combination of intravenous platinum and taxane chemotherapy. Over the past decade, three randomized phase III trials have been reported, and all have demonstrated a significant survival advantage for intraperitoneal compared with intravenous chemotherapy. However, there are potential barriers and controversies related to the administration of intraperitoneal chemotherapy in ovarian cancer patients. In this review, we discuss the evolution and current management considerations of chemotherapy for the treatment of epithelial ovarian cancer.
摘要
尽管在治疗方面取得了进展，但上皮性卵巢癌仍然是最致命的妇科恶性肿瘤。标准的治疗方法通常包括手术肿瘤减灭术和化疗的联合应用。几十年来，卵巢癌的化疗已经发展，目前包括静脉内铂类和紫杉烷类化疗的联合应用。在过去的十年中，已经报告了三项随机 III 期临床试验，所有这些试验都表明与静脉内化疗相比，腹腔内化疗具有显著的生存优势。然而，在卵巢癌患者中应用腹腔内化疗存在潜在的障碍和争议。在这篇综述中，我们讨论了治疗上皮性卵巢癌的化疗的演变和当前的管理考虑。
相似文献
1
Practical considerations in ovarian cancer chemotherapy.卵巢癌化疗的实际考虑因素。
Ther Adv Med Oncol. 2010 May;2(3):175-87. doi: 10.1177/1758834010361333.
2
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.比较尼拉帕利与铂类紫杉类联合化疗作为新诊断同源重组缺陷型 III/IV 期卵巢癌患者的新辅助治疗：开放标签、2 期、随机对照、多中心 OPAL 试验队列 C 的研究方案。
Trials. 2024 May 4;25(1):301. doi: 10.1186/s13063-024-08142-5.
3
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.专家共识：晚期或转移性上皮性卵巢癌的评估和管理。
Rev Colomb Obstet Ginecol. 2024 Jun 14;75(1):4094. doi: 10.18597/rcog.4094.
4
Optimal chemotherapy treatment for women with recurrent ovarian cancer.复发性卵巢癌女性的最佳化疗治疗。
Curr Oncol. 2007 Oct;14(5):195-208. doi: 10.3747/co.2007.148.
5
A systematic overview of chemotherapy effects in ovarian cancer.卵巢癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420.
6
Ovarian cancer: a brief historical overview of intraperitoneal trials.卵巢癌：腹膜内试验的简要历史概述
Ann Surg Oncol. 2014 May;21(5):1429-34. doi: 10.1245/s10434-013-3219-8. Epub 2013 Oct 1.
7
Intraperitoneal chemotherapy for women with ovarian cancer: nursing care and considerations.卵巢癌女性的腹腔内化疗：护理及注意事项
Clin J Oncol Nurs. 2008 Apr;12(2):265-71. doi: 10.1188/08.CJON.265-271.
8
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.OV21/PETROC：一项新辅助化疗和最佳肿瘤细胞减灭术后腹腔内与静脉化疗在卵巢上皮癌中的随机妇科癌症协作组 II 期研究。
Ann Oncol. 2018 Feb 1;29(2):431-438. doi: 10.1093/annonc/mdx754.
9
[INTRAVENOUS CHEMOTHERAPY VERSUS INTRAPERITONEAL CHEMOTHERAPY IN ADVANCED OVARIAN CANCER: UPDATE ON THE SITUATION WORLDWIDE AND IN ISRAEL].
Harefuah. 2015 Sep;154(9):594-8, 607, 606.
10
Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.细胞减灭术（CRS）联合腹腔热灌注化疗（HIPEC）治疗 HRR 突变的铂敏感复发性上皮性卵巢癌：一项 III 期随机临床试验。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221104565. doi: 10.1177/15330338221104565.
引用本文的文献
1
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on drug response genes to predict prognosis and therapeutic response in ovarian cancer.单细胞和批量RNA测序的综合分析基于药物反应基因鉴定出一种特征，以预测卵巢癌的预后和治疗反应。
Heliyon. 2024 Jun 20;10(13):e33367. doi: 10.1016/j.heliyon.2024.e33367. eCollection 2024 Jul 15.
2
Exosomes in diagnostic and therapeutic applications of ovarian cancer.外泌体在卵巢癌诊断和治疗中的应用。
J Ovarian Res. 2024 May 25;17(1):113. doi: 10.1186/s13048-024-01417-0.
3
Establishment of an optimized guinea pig model of cisplatin-induced ototoxicity.建立顺铂诱导耳毒性的优化豚鼠模型。
Front Vet Sci. 2023 Apr 13;10:1112857. doi: 10.3389/fvets.2023.1112857. eCollection 2023.
4
Pt(II)-PLGA Hybrid in a pH-Responsive Nanoparticle System Targeting Ovarian Cancer.靶向卵巢癌的pH响应性纳米粒子系统中的铂（II）-聚乳酸-羟基乙酸共聚物杂化物
Pharmaceutics. 2023 Feb 10;15(2):607. doi: 10.3390/pharmaceutics15020607.
5
Spontaneous Transformation of a p53 and Rb-Defective Human Fallopian Tube Epithelial Cell Line after Long Passage with Features of High-Grade Serous Carcinoma.经长期传代后，p53和Rb缺陷的人输卵管上皮细胞系发生自发转化，具有高级别浆液性癌的特征。
Int J Mol Sci. 2022 Nov 10;23(22):13843. doi: 10.3390/ijms232213843.
6
Tuning the Biological Activity of Camphorimine Complexes through Metal Selection.通过金属选择调节樟脑亚胺配合物的生物活性
Antibiotics (Basel). 2022 Jul 27;11(8):1010. doi: 10.3390/antibiotics11081010.
7
Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting.针对 HGF/c-MET 靶向的卵巢癌治疗策略。
Medicina (Kaunas). 2022 May 11;58(5):649. doi: 10.3390/medicina58050649.
8
Incidence, Mortality and Survival Analysis of Epithelial Ovarian Cancer in Brunei Darussalam.文莱达鲁萨兰国上皮性卵巢癌的发病率、死亡率和生存分析。
Asian Pac J Cancer Prev. 2022 Apr 1;23(4):1415-1423. doi: 10.31557/APJCP.2022.23.4.1415.
9
Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.妇科肿瘤学家对 II-IV 期卵巢癌患者辅助化疗护理的影响。
Gynecol Oncol. 2022 Jan;164(1):3-11. doi: 10.1016/j.ygyno.2021.11.001. Epub 2021 Nov 12.
10
Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers.基于纳米技术的药物递送与靶向治疗以克服卵巢癌的耐药性
Cancers (Basel). 2021 Oct 31;13(21):5480. doi: 10.3390/cancers13215480.
本文引用的文献
1
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.西地尼布是一种口服的血管内皮生长因子受体激酶抑制剂，在复发性上皮性卵巢癌、输卵管癌和腹膜癌中是一种有效药物。
J Clin Oncol. 2009 Nov 20;27(33):5601-6. doi: 10.1200/JCO.2009.23.2777. Epub 2009 Oct 13.
2
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.紫杉醇/铂类化疗六个疗程后完全缓解的晚期上皮性卵巢癌患者：观察与六个疗程紫杉醇对比的III期试验：After-6方案1的最终结果
J Clin Oncol. 2009 Oct 1;27(28):4642-8. doi: 10.1200/JCO.2009.21.9691. Epub 2009 Aug 24.
3
Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study.腹腔内注射卡铂联合静脉注射紫杉醇治疗残留病灶不理想的上皮性卵巢癌或原发性腹膜癌患者的II期研究：一项三开妇科癌症研究小组的研究
Int J Gynecol Cancer. 2009 Jul;19(5):834-7. doi: 10.1111/IGC.0b013e3181a29dfe.
4
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.对携带BRCA突变的肿瘤中聚（ADP - 核糖）聚合酶的抑制作用。
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
5
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.对接受初始铂类-紫杉醇治疗后获得完全缓解的晚期卵巢癌患者给予每3周一次或每12周一次紫杉醇（175mg/m²）治疗对生存的影响：西南肿瘤协作组和妇科肿瘤学组3期试验的随访
Gynecol Oncol. 2009 Aug;114(2):195-8. doi: 10.1016/j.ygyno.2009.04.012. Epub 2009 May 17.
6
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.培美曲塞治疗复发或持续性铂耐药卵巢癌或原发性腹膜癌的II期评估：妇科肿瘤学组的一项研究
J Clin Oncol. 2009 Jun 1;27(16):2686-91. doi: 10.1200/JCO.2008.19.2963. Epub 2009 Mar 30.
7
Intraperitoneal chemotherapy for ovarian cancer: 2009 goals.卵巢癌的腹腔内化疗：2009年目标。
Gynecol Oncol. 2009 Mar;112(3):439-40. doi: 10.1016/j.ygyno.2009.01.007.
8
Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.纳米白蛋白结合型紫杉醇在铂敏感的复发性卵巢癌、腹膜癌或输卵管癌患者中的II期评估。
J Clin Oncol. 2009 Mar 20;27(9):1426-31. doi: 10.1200/JCO.2008.18.9548. Epub 2009 Feb 17.
9
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.晚期卵巢癌新型铂类治疗方案的评估：妇科肿瘤协作组的一项III期试验
J Clin Oncol. 2009 Mar 20;27(9):1419-25. doi: 10.1200/JCO.2008.19.1684. Epub 2009 Feb 17.
10
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.一项关于两剂培美曲塞治疗铂耐药上皮性卵巢癌或原发性腹膜癌的随机、双盲、II期研究。
Eur J Cancer. 2009 May;45(8):1415-23. doi: 10.1016/j.ejca.2008.12.013. Epub 2009 Jan 23.
Zotero 插件